Clinical Trial

A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Name: A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis — clinical trial record (NCT07540442)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)

Trial Details

NCT Number	NCT07540442
Lead Sponsor	Shanghai Mabgeek Biotech.Co.Ltd
Conditions	Dermatitis, Atopic
Enrollment	180 participants
Start Date	2026-04-17
Primary Completion	2027-01-05 (estimated)
Study Completion	2027-11-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-20